A case of fatal hyperammonaemic encephalopathy in a patient with end-stage Multiple Myeloma treated with daratumumab

Main Article Content

Mauro Passucci
a:1:{s:5:"en_US";s:28:"La Sapienza University, Rome";}

Francesca Fazio
Department of Translational and Precision Medicine, La Sapienza University of Rome

Maria Teresa Petrucci
Department of Translational and Precision Medicine, La Sapienza University of Rome

Keywords

High risk Multiple Myeloma, hyperammonemia

Abstract

n.

Downloads

Download data is not yet available.


Abstract 540
PDF Downloads 772
HTML Downloads 330

References

1) Costa, L. J., & Usmani, S. Z. (2020). Defining and Managing High-Risk Multiple Myeloma: Current Concepts, Journal of the National Comprehensive Cancer Network J Natl Compr Canc Netw, 18(12), 1730-1737. Retrieved May 20, 2022, from https://jnccn.org/view/journals/jnccn/18/12/article-p1730.xml
2) Ikewaki J, Ogata M, Imamura T, Kohno K, Nakayama T, Kadota J. Development of hyperammonemic encephalopathy in patients with multiple myeloma may be associated with the appearance of peripheral blood myeloma cells. Leuk Lymphoma. 2009 Apr;50(4):667-9. doi: 10.1080/10428190902741489. PMID: 19373670.
3) Jaime Lora-Tamayo, Xavier Palom, José Sarrá, Oriol Gasch, Virginia Isern, Alberto Fernández de Sevilla, Ramón Pujol, Multiple Myeloma and Hyperammonemic Encephalopathy: Review of 27 Cases, Clinical Lymphoma and Myeloma, Volume 8, Issue 6, 2008, Pages 363-369, ISSN 1557-9190, https://doi.org/10.3816/CLM.2008.n.054.
4) Gertz MA, Buadi FK. Plasma cell leukemia. Haematologica. 2010;95(5):705-707. doi:10.3324/haematol.2009.021618
5) Howman R , Th akerer A , Pitman M , et al . Bortezomib, cyclophosphamide, and dexamethasone: highly eff ective for rapid reversal of myeloma-associated hyperammonemic encephalopathy . Leuk Lymphoma 2010 ; 51 : 2299 – 2302.
6) Amit Patel, Umeer Waheed, Stephen J. Brett, Amin Rahemtulla, Jane F. Apperley & Parind B. Patel (2014) Rapid initial response of myeloma hyperammonemic encephalopathy to L-ornithine-L-aspartate and dexamethasone therapy, Leukemia & Lymphoma, 55:1, 198-200
7) Anthony Pham, John L. Reagan, Jorge J Castillo; Plasma Cell Myeloma Causing Hyperammonemia Associated with High Inpatient Mortality. Blood 2012; 120 (21): 5002. doi: https://doi.org/10.1182/blood.V120.21.5002.5002
8) Murtaza G, Lu H, Faqah A, Konowitz N, Kuruvilla A, Adhikari S. Multiple Myeloma-Induced Hyperammonemic Encephalopathy. J Hematol. 2017;6(1):29-31. doi:10.14740/jh322e

Article Sidebar

PDF HTML
Published
Jan 1, 2023
DOI https://doi.org/10.4084/MJHID.2023.012

Article Details

How to Cite

Passucci, M., Fazio, F. and Petrucci, M. T. (2023) “A case of fatal hyperammonaemic encephalopathy in a patient with end-stage Multiple Myeloma treated with daratumumab”, Mediterranean Journal of Hematology and Infectious Diseases, 15(1), p. e2023012. doi: 10.4084/MJHID.2023.012.
Issue
Vol. 15 No. 1 (2023): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
Section
Letters to the Editor
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.